HomeBUSINESS
BUSINESS

Interprotein, Takeda Sign Collaboration Agreement on Molecular Design for PPI Modulators
(Jan.12.2012)

The drug discovery venture company Interprotein Corporation has entered into a collaborative agreement with Takeda Pharmaceutical for Interprotein’s molecular design technology for protein-protein interaction (PPI) modulators. Under the terms of the agreement, Interprotein will design low molecular weight compounds as requested by Takeda for target PPI in the field of cancer, utilizing its unique platform technology “Interprotein’s Engine for New Drug Design” (INTENDD). Takeda will utilize the results of the collaboration for its drug discovery. The agreement was concluded on December 26.
(LOG IN FOR FULL STORY)

News Calendar